CT53518, a novel selective FLT3 antagonist for the sorted by
relevance

Admin14.07.2021

CT53518, a novel selective FLT3 antagonist for the

8002
Admin24.08.2021

CT53518, a novel selective FLT3 antagonist for the

9204
Admin26.09.2021

CT53518, a novel selective FLT3 antagonist for the

3600
Admin30.07.2021

CT53518, a novel selective FLT3 antagonist for the

3804
Admin13.07.2021

CT53518, a novel selective FLT3 antagonist for the

702
Admin25.09.2021

CT53518, a novel selective FLT3 antagonist for the

401
Admin08.09.2021

CT53518, a novel selective FLT3 antagonist for the

6103
Admin22.07.2021

CT53518, a novel selective FLT3 antagonist for the

4009
Admin28.08.2021

CT53518, a novel selective FLT3 antagonist for the

2104
Admin31.07.2021

CT53518, a novel selective FLT3 antagonist for the

7801
Admin31.08.2021

CT53518, a novel selective FLT3 antagonist for the

9801
Admin17.08.2021

CT53518, a novel selective FLT3 antagonist for the

5408
Admin23.09.2021

CT53518, a novel selective FLT3 antagonist for the

72010
Admin20.07.2021

(PDF) Phase 1 clinical results with tandutinib (MLN518), a

11010
Admin10.09.2021

Relation between inhibition of FLT3 phosphorylation in

7303
Admin29.07.2021

Distribution of KIT mutations in GISTs. | Download

309
Admin09.09.2021

Flt Inhibition | Flt3 Mutation | Flt Inhibitor Review

7205
Admin13.08.2021

Tandutinib phase 1 experience: patient characteristics

5506
Admin08.08.2021

Tandutinib plasma concentration versus time profile for a

1809
Admin30.07.2021

Change in day-28 rate-corrected QT interval (QTc) from

1401
Admin15.08.2021

Risk stratification of primary GIST by mitotic index, size

7807